The largest study on the Pfizer-BioNTech <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine </a>so far has found that the drug provided more than 95 per cent protection against the <a href="https://www.wionews.com/topics/coronavirus">deadly virus</a>, but these numbers significantly drop when only one of the two prescribed doses are taken.&nbsp;

An analysis of public health data from Israel revealed that the vaccine was even very effective for the elderly even at a time when a more infectious English variant was raising concerns.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-pfizers-bumper-profit-from-vaccine-sales-383086/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

In Israel, about 5 million people have received two doses of Pfizer/BioNTech vaccine, making the country one of the leaders in fully vaccinating its adults with more than 70 per cent of the population inoculated.&nbsp;

The study, published in the Lancet medical journal, found that the two shots of the vaccine provide 95.3 per cent protection against infection and 96.7 per cent protection against death seven days after the second dose.&nbsp;

This protection increased to 96.5 and 98 per cent respectively after 14 days.

Also read | <a href="https://www.wionews.com/world/canada-becomes-first-country-to-authorise-pfizer-covid-vaccine-for-kids-age-12-and-up-383033">Canada becomes first country to authorise Pfizer Covid vaccine for kids age 12 and up</a>

However, the study found, that the protection was extremely low when a single dose of Pfizer-BioNTech vaccine is taken.&nbsp;

Between seven and 14 days after taking the first dose, the protection appeared 57.7 per cent against infection and 77 per cent against death.&nbsp;

(With inputs from agencies)

The largest study on the Pfizer-BioNTech coronavirus vaccine so far has found that the drug provided more than 95 per cent protection against the deadly virus, but these numbers significantly drop when only one of the two prescribed doses are taken.

The largest study on the Pfizer-BioNTech coronavirus vaccine so far has found that the drug provided more than 95 per cent protection against the deadly virus, but these numbers significantly drop when only one of the two prescribed doses are taken. An analysis of public health data from Israel revealed that the vaccine was even very effective for the elderly even at a time when a more infectious English variant was raising concerns. Watch | In Israel, about 5 million people have received two doses of Pfizer/BioNTech vaccine, making the country one of the leaders in fully vaccinating its adults with more than 70 per cent of the population inoculated. The study, published in the Lancet medical journal, found that the two shots of the vaccine provide 95.3 per cent protection against infection and 96.7 per cent protection against death seven days after the second dose. This protection increased to 96.5 and 98 per cent respectively after 14 days. Also read | Canada becomes first country to authorise Pfizer Covid vaccine for kids age 12 and up However, the study found, that the protection was extremely low when a single dose of Pfizer-BioNTech vaccine is taken. Between seven and 14 days after taking the first dose, the protection appeared 57.7 per cent against infection and 77 per cent against death. (With inputs from agencies)

Largest study on Pfizer Covid vaccine says drug offers over 95% protection

BioNTECh-Pfizer claimed on Wednesday that their <a href="https://www.wionews.com/topics/coronavirus-vaccine">coronavirus vaccine </a>has an efficacy of 100 per cent in the 12 to 15-year-old age group.&nbsp;

Phase 3 trials conducted on 2,260 adolescents in the US showed "100 per cent efficacy and robust antibody responses", the pharma giants said in a statement.&nbsp;

Watch |&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/scientists-will-need-new-vaccine-to-fight-covid-19-in-a-year-374419/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

"We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year," Pfizer chief executive Albert Bourla was quoted as saying by news agency AFP.&nbsp;

BioNTech CEO said the vaccine's results on teens were "very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant".&nbsp;

Also read | <a href="https://www.wionews.com/world/china-denies-whos-accusation-of-not-sharing-covid-data-374468">China denies WHO's accusation of not sharing COVID data</a>

The vaccine, approved by the Western nations last year, uses mRNA technology.

It is approved for people aged 16 and above in the US and the European Union.&nbsp;

A real-world study of 1.2 million people in Israel found that the vaccine is 94 per cent effective.&nbsp;

Last week, BioNTech-Pfizer started studies to find the drug's effect on children, with the age group of 5-11 being the first to get the vaccine.

BioNTECh-Pfizer claimed on Wednesday that their coronavirus vaccine has an efficacy of 100 per cent in the 12 to 15-year-old age group. Phase 3 trials conducted on 2,260 adolescents in the US showed "100 per cent efficacy and robust antibody responses", the pharma giants said in a statement.

BioNTECh-Pfizer claimed on Wednesday that their coronavirus vaccine has an efficacy of 100 per cent in the 12 to 15-year-old age group. Phase 3 trials conducted on 2,260 adolescents in the US showed "100 per cent efficacy and robust antibody responses", the pharma giants said in a statement. Watch | "We plan to submit these data to (US regulator) FDA as a proposed amendment to our Emergency Use Authorisation in the coming weeks and to other regulators around the world, with the hope of starting to vaccinate this age group before the start of the next school year," Pfizer chief executive Albert Bourla was quoted as saying by news agency AFP. BioNTech CEO said the vaccine's results on teens were "very encouraging given the trends we have seen in recent weeks regarding the spread of the B.1.1.7 UK variant". Also read | China denies WHO's accusation of not sharing COVID data The vaccine, approved by the Western nations last year, uses mRNA technology. It is approved for people aged 16 and above in the US and the European Union. A real-world study of 1.2 million people in Israel found that the vaccine is 94 per cent effective. Last week, BioNTech-Pfizer started studies to find the drug's effect on children, with the age group of 5-11 being the first to get the vaccine.

BioNTech-Pfizer say their Covid-19 vaccine has 100% efficacy in 12-15 year olds

pfizer-vaccine-efficacy

Pfizer Vaccine Efficacy, News on Pfizer Vaccine Efficacy, stories on Pfizer Vaccine Efficacy, articles on Pfizer Vaccine Efficacy, Pfizer Vaccine Efficacy stories at Wion, Pfizer Vaccine Efficacy news, Pfizer Vaccine Efficacy latest news

pfizer vaccine-efficacy

Largest study on Pfizer Covid vaccine says drug offers over 95% protection

BioNTech-Pfizer say their Covid-19 vaccine has 100% efficacy in 12-15 year olds